437 related articles for article (PubMed ID: 24690241)
21. Nanobody-based cancer therapy of solid tumors.
Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
[TBL] [Abstract][Full Text] [Related]
22. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
Al-Baradie RS
Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
[TBL] [Abstract][Full Text] [Related]
23. [Structural Life Science towards the Regulation of Selective GPCR Signaling].
Kobayashi T
Yakugaku Zasshi; 2016; 136(2):179-84. PubMed ID: 26831790
[TBL] [Abstract][Full Text] [Related]
24. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update.
Hutchings CJ
Expert Opin Biol Ther; 2020 Aug; 20(8):925-935. PubMed ID: 32264722
[TBL] [Abstract][Full Text] [Related]
25. Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics.
Mir MA; Mehraj U; Sheikh BA; Hamdani SS
Hum Antibodies; 2020; 28(1):29-51. PubMed ID: 31322555
[TBL] [Abstract][Full Text] [Related]
26. Nanobodies as sensors of GPCR activation and signaling.
El Daibani A; Che T
Methods Cell Biol; 2021; 166():161-177. PubMed ID: 34752331
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.
Lappano R; Maggiolini M
Drugs; 2017 Jun; 77(9):951-965. PubMed ID: 28401445
[TBL] [Abstract][Full Text] [Related]
28. The development of nanobodies for therapeutic applications.
Van Bockstaele F; Holz JB; Revets H
Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
[TBL] [Abstract][Full Text] [Related]
29. Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.
Zare H; Aghamollaei H; Hosseindokht M; Heiat M; Razei A; Bakherad H
Mol Cell Probes; 2021 Feb; 55():101692. PubMed ID: 33358936
[TBL] [Abstract][Full Text] [Related]
30. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases.
Douthwaite JA; Finch DK; Mustelin T; Wilkinson TC
Pharmacol Ther; 2017 Jan; 169():113-123. PubMed ID: 27153991
[TBL] [Abstract][Full Text] [Related]
31. Small molecules targeting heterotrimeric G proteins.
Ayoub MA
Eur J Pharmacol; 2018 May; 826():169-178. PubMed ID: 29522725
[TBL] [Abstract][Full Text] [Related]
32. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
Heilker R; Wolff M; Tautermann CS; Bieler M
Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
[TBL] [Abstract][Full Text] [Related]
33. Antibody fragments for stabilization and crystallization of G protein-coupled receptors and their signaling complexes.
Shukla AK; Gupta C; Srivastava A; Jaiman D
Methods Enzymol; 2015; 557():247-58. PubMed ID: 25950968
[TBL] [Abstract][Full Text] [Related]
34. Physiological relevance of GPCR oligomerization and its impact on drug discovery.
Panetta R; Greenwood MT
Drug Discov Today; 2008 Dec; 13(23-24):1059-66. PubMed ID: 18824244
[TBL] [Abstract][Full Text] [Related]
35. Transforming nanobodies into high-precision tools for protein function analysis.
Gettemans J; De Dobbelaer B
Am J Physiol Cell Physiol; 2021 Feb; 320(2):C195-C215. PubMed ID: 33264078
[TBL] [Abstract][Full Text] [Related]
36. GPCR-2L: predicting G protein-coupled receptors and their types by hybridizing two different modes of pseudo amino acid compositions.
Xiao X; Wang P; Chou KC
Mol Biosyst; 2011 Mar; 7(3):911-9. PubMed ID: 21180772
[TBL] [Abstract][Full Text] [Related]
37. Mapping cytoskeletal protein function in cells by means of nanobodies.
Van Audenhove I; Van Impe K; Ruano-Gallego D; De Clercq S; De Muynck K; Vanloo B; Verstraete H; Fernández LÁ; Gettemans J
Cytoskeleton (Hoboken); 2013 Oct; 70(10):604-22. PubMed ID: 23818458
[TBL] [Abstract][Full Text] [Related]
38. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
Saleh N; Ibrahim P; Clark T
Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
[TBL] [Abstract][Full Text] [Related]
39. GPCR-GIP networks: a first step in the discovery of new therapeutic drugs?
Bockaert J; Dumuis A; Fagni L; Marin P
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):649-57. PubMed ID: 15503867
[TBL] [Abstract][Full Text] [Related]
40. Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors.
Hudson BD; Smith NJ; Milligan G
Adv Pharmacol; 2011; 62():175-218. PubMed ID: 21907910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
